193 related articles for article (PubMed ID: 27097910)
1. Underutilization of gene expression profiling for early-stage breast cancer in California.
Cress RD; Chen YS; Morris CR; Chew H; Kizer KW
Cancer Causes Control; 2016 Jun; 27(6):721-7. PubMed ID: 27097910
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
3. Influence of provider factors and race on uptake of breast cancer gene expression profiling.
Reeder-Hayes KE; Wheeler SB; Baggett CD; Zhou X; Meng K; Roberts MC; Carey LA; Meyer AM
Cancer; 2018 Apr; 124(8):1743-1751. PubMed ID: 29338090
[TBL] [Abstract][Full Text] [Related]
4. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
5. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
6. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
7. Disparities in Breast Cancer Survival by Socioeconomic Status Despite Medicare and Medicaid Insurance.
Silber JH; Rosenbaum PR; Ross RN; Reiter JG; Niknam BA; Hill AS; Bongiorno DM; Shah SA; Hochman LL; Even-Shoshan O; Fox KR
Milbank Q; 2018 Dec; 96(4):706-754. PubMed ID: 30537364
[TBL] [Abstract][Full Text] [Related]
8. A tracking and feedback registry to reduce racial disparities in breast cancer care.
Bickell NA; Shastri K; Fei K; Oluwole S; Godfrey H; Hiotis K; Srinivasan A; Guth AA
J Natl Cancer Inst; 2008 Dec; 100(23):1717-23. PubMed ID: 19033569
[TBL] [Abstract][Full Text] [Related]
9. Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment.
Hassett MJ; Schymura MJ; Chen K; Boscoe FP; Gesten FC; Schrag D
Cancer; 2016 Feb; 122(3):420-31. PubMed ID: 26536043
[TBL] [Abstract][Full Text] [Related]
10. Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor-Positive Breast Cancer.
Roberts MC; Kurian AW; Petkov VI
J Natl Compr Canc Netw; 2019 Jun; 17(6):662-668. PubMed ID: 31200352
[TBL] [Abstract][Full Text] [Related]
11. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
12. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65.
O'Neill SC; Isaacs C; Lynce F; Graham DM; Chao C; Sheppard VB; Zhou Y; Liu C; Selvam N; Schwartz MD; Potosky AL
Breast Cancer Res; 2017 Mar; 19(1):45. PubMed ID: 28359319
[TBL] [Abstract][Full Text] [Related]
14. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
[TBL] [Abstract][Full Text] [Related]
15. Low utility of Oncotype DX® in the clinic.
Ricks-Santi LJ; McDonald JT
Cancer Med; 2017 Mar; 6(3):501-507. PubMed ID: 28145091
[TBL] [Abstract][Full Text] [Related]
16. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in treatment and survival among women with early-stage breast cancer.
Hershman D; McBride R; Jacobson JS; Lamerato L; Roberts K; Grann VR; Neugut AI
J Clin Oncol; 2005 Sep; 23(27):6639-46. PubMed ID: 16170171
[TBL] [Abstract][Full Text] [Related]
18. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
Griggs JJ; Hawley ST; Graff JJ; Hamilton AS; Jagsi R; Janz NK; Mujahid MS; Friese CR; Salem B; Abrahamse PH; Katz SJ
J Clin Oncol; 2012 Sep; 30(25):3058-64. PubMed ID: 22869890
[TBL] [Abstract][Full Text] [Related]
20. Disparities in pancreas cancer care.
Abraham A; Al-Refaie WB; Parsons HM; Dudeja V; Vickers SM; Habermann EB
Ann Surg Oncol; 2013 Jun; 20(6):2078-87. PubMed ID: 23579872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
